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Introduction
Angiogenesis defines the formation of new blood vessels from pre-
existing vessels and is crucial for normal physiological vascular
development, as well as for the pathological development of certain
diseases, including diabetic retinopathy, atherosclerosis and cancer
(Carmeliet, 2005). VEGF is a potent inducer of angiogenesis and is
vital for vascular development, both during embryogenesis and in
early neonatal life (Carmeliet et al., 1996; Ferrara et al., 1996;
Gerber et al., 1999). Furthermore, VEGF is a key regulator of
endothelial cell survival in the tumour vasculature (Benjamin and
Keshet, 1997; Liu et al., 2000). It activates a number of receptor
tyrosine kinases that are present on endothelial cells. VEGF receptor-
1 (VEGFR-1/Flt-1) and VEGFR-2 (Flk-1/KDR) are present on
vascular endothelial cells, whereas expression of VEGFR-3 (Flk-4)
is confined to lymphatic endothelial cells (Cross et al., 2003; Lohela
et al., 2009; Olsson et al., 2006). Numerous studies have revealed
that activation of VEGFR-2 by the VEGF-A ligand is responsible
for mediating the majority of physiological effects of VEGF in
endothelial cells, including proliferation, migration, survival and
permeability (Holmes et al., 2007). Identification of intracellular
signalling pathways involved in VEGF–VEGFR-2 signalling has
been subject to intense research in an attempt to decipher the crucial
components downstream of VEGFR-2 (Holmes et al., 2007).
Mitogen-activated protein kinases (MAPKs) regulate the
transduction of extracellular growth factor or stress-induced stimuli
from the cell membrane to nuclear or cytoplasmic targets, and are
crucial for the control of numerous cellular processes, including
proliferation, migration and survival in response to these
extracellular cues (Qi and Elion, 2005). Four major MAPK
signalling cascades have been identified in mammalian cells:
extracellular signal-regulated kinases 1 and 2 (ERK1/2), Jun-N-
terminal kinases 1, 2 and 3 (JNK1–JNK3), p38 MAPKs (p38, 
-, - and -), and the most recently discovered MAPK, ERK5
(Chang and Karin, 2001; Roberts et al., 2009; Wang and Tournier,
2006). Each of these MAPKs is able to phosphorylate and activate
a range of downstream substrates, resulting in specific intracellular
responses (Lewis et al., 1998).
The ERK5 signalling module consists of MEKK2/3
(MAPK/ERK kinase kinase 2 and 3), which phosphorylates
MEK5 (MAPK/ERK kinase 5), which in turn activates ERK5 by
dual phosphorylation of Thr218 and Tyr220 within a T-E-Y
activation motif. The physiological importance of the ERK5
signalling cascade was revealed in studies of targeted deletion of
either Erk5 (Regan et al., 2002; Sohn et al., 2002; Yan et al.,
2003), Mek5 (Wang et al., 2005), or Mekk3 (Yang et al., 2000) in
mice. Deletion of any of these genes resulted in death between
embryonic day 9.5 (E9.5) and E11.5 as a result of hemorrhaging
caused by severe abnormalities in cardiovascular development
and compromised vascular integrity. Importantly, targeted deletion
of Erk5 in murine endothelial cells, but not in other cell types
such as cardiomyocytes and hepatocytes, was also found to result
in cardiovascular defects and disrupted vascular integrity, a
phenotype that is identical to that of the global Erk5 knockout
mouse (Hayashi et al., 2004; Hayashi and Lee, 2004). These data
suggest that although ERK5 is expressed in a variety of tissues,
expression of ERK5 within the endothelium is crucial to preserve
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Summary
Extracellular signal-regulated kinase 5 (ERK5) is activated in response to environmental stress and growth factors. Gene ablation of
Erk5 in mice is embryonically lethal as a result of disruption of cardiovascular development and vascular integrity. We investigated
vascular endothelial growth factor (VEGF)-mediated ERK5 activation in primary human dermal microvascular endothelial cells
(HDMECs) undergoing proliferation on a gelatin matrix, and tubular morphogenesis within a collagen gel matrix. VEGF induced
sustained ERK5 activation on both matrices. However, manipulation of ERK5 activity by siRNA-mediated gene silencing disrupted
tubular morphogenesis without impacting proliferation. Overexpression of constitutively active MEK5 and ERK5 stimulated tubular
morphogenesis in the absence of VEGF. Analysis of intracellular signalling revealed that ERK5 regulated AKT phosphorylation. On
a collagen gel, ERK5 regulated VEGF-mediated phosphorylation of the pro-apoptotic protein BAD and increased expression of the
anti-apoptotic protein BCL2, resulting in decreased caspase-3 activity and apoptosis suppression. Our findings suggest that ERK5 is
required for AKT phosphorylation and cell survival and is crucial for endothelial cell differentiation in response to VEGF.
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vascular integrity, and to maintain normal endothelial cell function
(Roberts et al., 2009).
ERK5 is activated by a range of extracellular stimuli, including
the pro-angiogenic growth factors VEGF and FGF-2 (fibroblast
growth factor-2) in endothelial cells (Hayashi et al., 2004). The
finding that ERK5 is required for tumour-associated angiogenesis
(Hayashi et al., 2005) raises the possibility that ERK5 is a crucial
component of the VEGF-signalling cascade in endothelial cells.
However, the physiological importance of VEGF-stimulated ERK5
activation, and the downstream targets of VEGF-induced ERK5
activity have yet to be determined.
In this study, we addressed this issue by profiling VEGF-
stimulated ERK5 activation in primary human dermal
microvascular endothelial cells (HDMECs), and characterised the
functional effects of modulation of ERK5 activation in models of
distinct stages of the angiogenic process. Activation of ERK5 was
observed under conditions of both VEGF-induced HDMEC
proliferation and VEGF-induced tubular morphogenesis of
HDMECs in a three-dimensional collagen gel. However, only
VEGF-stimulated tubular morphogenesis was affected by ERK5
downregulation. We show that ERK5 activity is required for VEGF-
mediated activation of AKT and the resulting phosphorylation of
BAD, leading to the prevention of endothelial cell apoptosis.
Together, our data reveal for the first time, that ERK5 is a crucial
mediator of VEGF-induced endothelial cell survival during
conditions of tubular morphogenesis. Furthermore, our results
suggest that the ERK5 pathway represents a viable target for the
development of specific inhibitors aimed at preventing tumour-
associated angiogenesis.
Results
VEGF stimulates sustained ERK5 activity in human
endothelial cells during proliferation and differentiation
We used primary HDMECs to study the role of VEGF-mediated
ERK5 activity. In response to VEGF stimulation, HDMECs
proliferate on a gelatin matrix, but undergo tubular morphogenesis
to form capillary vessels in a 3D collagen gel (Fig. 1A). Cell
cycle analysis following stimulation with VEGF for 24 hours
revealed that cells within collagen gel structures were cell cycle
arrested (Fig. 1B). By contrast, VEGF-treated HDMECs plated
on a gelatin matrix underwent proliferation, demonstrated by a
significant number of cells in the S and G2–M phases of the cell
cycle (Fig. 1B). The proliferation and differentiation of endothelial
cells represent distinct aspects of the angiogenic response to
VEGF in vivo, where endothelial cells must first digest the
basement membrane, migrate and proliferate to form a sprout,
before eventually differentiating into a functional lumen-
containing vessel (Koike et al., 2004; Montesano et al., 1983).
Immunoblot analysis of cell lysates using a phospho-ERK5
antibody, which is directed against the phosphorylated Thr218
and Tyr220 residues within the T-E-Y motif in the ERK5
activation loop, revealed that VEGF stimulation induced a
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Fig. 1. VEGF stimulates activation of ERK5
under conditions of HDMEC proliferation
and tubular morphogenesis.
(A)Morphology of HDMECs on gelatin and
collagen I matrices. Serum-starved HDMECs
were seeded on gelatin (i–iv), or between two
layers of collagen I (v–viii). Unstimulated
cells were fixed immediately (0 h), or at 3, 9 or
24 hours after stimulation with 50 ng/ml
VEGF on both matrices. HDMECs plated on a
collagen I matrix underwent VEGF-induced
tubular morphogenesis by 24 hours (viii).
Cells were fixed, HDMEC actin stress fibres,
and nuclei were stained with Rhodamine-
coupled Phalloidin (red) and Hoechst 33342
(blue), respectively (ix). Scale bars: 100m.
(B)Analysis of cell cycle distribution of
VEGF-stimulated HDMECs plated on gelatin
and collagen I matrices. HDMECs were
seeded on a gelatin matrix, or between two
layers of collagen I before stimulation with 50
ng/ml VEGF for 24 hours. Cells were
harvested and the percentage of cells in phases
G0–G1 or S+(G2–M) of the cell cycle were
determined by FACS analysis. (C)HDMECs
were serum starved for 20 hours before
seeding on a gelatin matrix, or between two
layers of collagen I, and stimulated with 50
ng/ml VEGF. Cells were lysed at the indicated
times, and cell lysates were resolved by 10%
SDS-PAGE, and analysed by western blotting
(WB). (D)The degree of ERK5 and ERK1/2
phosphorylation, relative to actin, was
quantified by densitometric analysis. Results
are from one experiment, which is
representative of three.
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sustained activation of ERK5 in HDMECs on both gelatin and
collagen matrices (Fig. 1C,D). VEGF did not induce any changes
in the total level of the ERK5 protein (Fig. 1C) in HDMECs on
either matrix. In contrast to the activation of ERK5, VEGF
induced a relatively transient activation of ERK1/2, which
returned to basal levels by 3 hours on a gelatin matrix and by 1
hour in a collagen gel (Fig. 1C,D).
VEGF-stimulated ERK5 activity is required for tubular
morphogenesis but not cell proliferation
It is well established that VEGF is a potent inducer of endothelial
cell proliferation in vitro (Ferrara and Henzel, 1989; Kroll and
Waltenberger, 1997; Leung et al., 1989). To explore the potential
involvement of ERK5 in HDMEC proliferation and tubular
morphogenesis we used two separate siRNA duplexes targeting
ERK5. Both of these duplexes downregulated ERK5 protein
expression levels by 97%, as determined by western blot analysis
(Fig. 2A). HDMECs plated on a gelatin matrix underwent a
doubling in cell number following stimulation with VEGF for 3
days (Fig. 2B). ERK5 silencing had no significant effect on VEGF-
induced cellular proliferation (Fig. 2B). By contrast, siRNA-
mediated ERK5 silencing had a profound effect on VEGF-induced
HDMEC tubular morphogenesis, because endothelial cells failed
to form a network of vessels in collagen gel in response to VEGF
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Fig. 2. Downregulation of ERK5 expression inhibits VEGF-induced HDMEC tubular morphogenesis but not proliferation. (A)HDMECs were transfected
with 10 nM ERK5 siRNA1, 10 nM ERK5 siRNA2, 10 nM non-silencing (N.S.) siRNA or left untransfected (Untrans.). Cells were lysed 48 hours after transfection,
and separated on a 10% SDS-PAGE gel before western blot (WB) analysis with antibodies directed against ERK5 and actin, as indicated. ERK5 expression,
relative to actin, was quantified by densitometric analysis. (B)24 hours after transfection, HDMECs were seeded at 1.5104 cells per well on a gelatin matrix for
24 hours, before serum starvation for 20 hours, followed by stimulation with or without VEGF (50 ng/ml) for 72 hours. Cell numbers were quantified by Cell-Titer
Glo® luminescence assay. Data are presented as cell number (n3, mean ± s.d.; n.s., not significant). (C)24 hours after transfection, HDMECs were serum starved
for 20 hours and seeded between two layers of collagen I before stimulation with VEGF (50 ng/ml) for 24 hours. Cells were fixed, HDMEC actin stress fibres and
nuclei were stained with Rhodamine-coupled Phalloidin (red) and Hoechst 33342 (blue), respectively. (D)The total length of tubular structures was quantified from
three fields (10 objective) per well (n3, mean ± s.d.; **P<0.01). (E)HDMECs were transfected with 10 nM ERK5 siRNA (5 nM ERK5 siRNA1 + 5 nM ERK5
siRNA2) or with 10 nM of non-silencing (N.S.) siRNA. 24 hours after transfection, cells were serum starved for 20 hours, before seeding on gelatin or between two
layers of collagen I, and stimulation with VEGF (50 ng/ml). 1 hour after VEGF stimulation, cells were stained with annexin V Alexa Fluor® 488 conjugate (green)
and Hoechst 33342 (blue). (F)Quantification of early apoptosis in siRNA-transfected HDMECs after 1 hour of tube formation (collagen) or proliferation (gelatin)
relative to N.S. siRNA control (n3, mean ± s.d.; **P<0.01; n.s., not significant).
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(Fig. 2C,D). Cells appeared rounded, with pyknotic hypercondensed
nuclei, indicative of cell death. Assessment of early apoptosis of
HDMECs by annexin V staining of phosphatidylserine levels on
the outer layer of the plasma membrane revealed that within
collagen gels, cells treated with ERK5 siRNA displayed a fourfold
increase in apoptosis compared with cells transfected with non-
silencing (N.S.) control siRNA (Fig. 2E,F). By contrast, ERK5
siRNA-treated cells plated on a gelatin matrix showed no significant
difference in the number of annexin V-positive cells, compared
with that of the N.S. siRNA-treated cells (Fig. 2E,F). This data
suggests that in HDMECs, ERK5 is required for VEGF-stimulated
survival during tubular morphogenesis, but is not required during
VEGF-induced cellular proliferation. In contrast to ERK5, siRNA-
mediated silencing of ERK1 and ERK2 expression inhibited VEGF-
mediated proliferation of HDMECs (supplementary material Fig.
S1B). Silencing of ERK1 had a small inhibitory effect on tubular
morphogenesis, with tube length reduced by 15%, whereas
silencing of ERK2 had no effect on tubular morphogenesis
(supplementary material Fig. S1C,D). These data reveal that, in
HDMECs, ERK5 and ERK1/2 appear to have distinct roles; ERK5
regulating tubular morphogenesis and ERK1/2 regulating cellular
proliferation.
ERK5 is required for VEGF-stimulated AKT
phosphorylation and suppression of caspase-3 activity
during tubular morphogenesis
The profound effect of silencing ERK5 on HDMEC tubular
morphogenesis with a concomitant increase in annexin V staining
(Fig. 2E), led us to analyse the activation of pathways regulating
apoptosis in HDMECs. VEGF stimulated phosphorylation of the
VEGFR-2 on both gelatin and collagen matrices; an effect that
was not altered by silencing ERK5 expression (Fig. 3A). VEGF-
induced activation of the serine/threonine kinase AKT/protein
kinase B (PKB) is crucial for protecting endothelial cells against
apoptosis (Fujio and Walsh, 1999; Gerber et al., 1998b). We
analysed the phosphorylation status of AKT on Ser473 and Thr308
in HDMECs in response to acute VEGF stimulation when plated
on a collagen matrix and a gelatin matrix. Treatment of HDMECs
with siRNA duplexes against ERK5 resulted in decreased
phosphorylation of AKT by approximately 50% in response to
VEGF on a gelatin matrix compared with untransfected cells and
cells transfected with N.S. siRNA. By contrast, on a collagen
matrix the inhibition was more profound, with AKT
phosphorylation reduced by at least 94% (Fig. 3A). Importantly,
the total level of AKT protein was not affected on either matrix,
thus indicating that the inhibition of ERK5 activity was affecting
AKT phosphorylation (Fig. 3A). AKT is known to regulate the
activity of a number of signalling proteins, including the pro-
apoptotic protein BAD (Datta et al., 1997) and the anti-apoptotic
protein BCL2 (Pugazhenthi et al., 2000). Phosphorylation of
BAD on Ser136 by AKT prevents BAD from interacting with
BCL2 by sequestering BAD to the 14-3-3 protein (Datta et al.,
1997; Zha et al., 1996). Acute VEGF-stimulation of HDMECs
resulted in increased BAD phosphorylation on Ser136; an affect
that was more pronounced on the collagen matrix (Fig. 3A).
Treatment of HDMECs with siRNA duplexes against ERK5
resulted in a decrease in VEGF-induced phosphorylation of BAD
(Fig. 3A). Furthermore, silencing of ERK5 also inhibited the
ability of VEGF to stimulate increased BCL2 mRNA expression
in HDMECs: an effect that was more pronounced within a
collagen gel (Fig. 3B).
Activation of the protease family of caspases represents one of
the terminal stages of signal transduction pathways that lead to
apoptosis in endothelial cells (Pober et al., 2009). We analysed the
effect of silencing ERK5 on the activity of caspase-3/7 in HDMECs
plated on a gelatin or collagen matrix 1 hour, 6 hours and 24 hours
after stimulation with VEGF, using a fluorescent-based assay.
Comparison of the two matrices revealed that after 24 hours under
basal conditions, caspase-3/7 activity was induced on the collagen
gel; an effect that was suppressed by addition of VEGF (Fig. 4F).
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Fig. 3. ERK5 activation is required for VEGF-stimulated
phosphorylation of AKT and BAD and maintaining BCL2
expression levels during tubular morphogenesis.
(A)HDMECs were transfected with 10 nM ERK5 siRNA1, 10
nM ERK5 siRNA2, 10 nM non-silencing (N.S.) siRNA or left
untransfected (Untrans.). 24 hours after transfection, cells were
serum starved for 20 hours before plating on a gelatin matrix, or
between two layers of a type I collagen gel and stimulated, or
not, with VEGF (50 ng/ml) for 10 minutes. Cells were lysed in
RIPA buffer and cell lysates were resolved by 10% SDS-PAGE
and analysed by western blotting (WB). The expression of
ERK5 relative to actin was quantified by densitometric
analysis. (B)HDMECs were transfected with 5 nM ERK5
siRNA1 and 5 nM ERK5 siRNA2, or with 10 nM non-silencing
(N.S.) siRNA. 24 hours after transfection, cells were serum
starved for 20 hours, before plating on a gelatin matrix, or onto
a collagen type I gel and stimulated with VEGF (50 ng/ml) for
3 and 9 hours. Total RNA was extracted and BCL2 mRNA
levels were quantified by qRT-PCR. Data are presented as level
of BCL2 mRNA relative to the value at 0 hour (n3; mean ±
s.d.).
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Addition of staurosporine (STS), a known inducer of apoptosis in
endothelial cells (Kabir et al., 2002), was used as a positive control
and induced maximal caspase-3/7 activity on both matrices (Fig.
4A–F). Silencing of ERK5 only induced caspase-3/7 activity in
HDMECs plated in a collagen matrix; an effect that was evident 1
hour after cells had been plated in a collagen gel (Fig. 4B). Loss
of ERK5 induced maximal apoptosis after 6 hours, and was still
evident after 24 hours; an effect that was confined to the collagen
matrix (Fig. 4C–F). The presence of VEGF was not sufficient to
suppress ERK5-induced cleaved caspase-3 expression at any time
point (Fig. 4A–F). To confirm the role of active caspase-3 in
HDMEC apoptosis caused by loss of ERK5, we analysed the
levels of the 17 kDa and 19 kDa cleaved caspase-3 proteolytic
fragments by western blotting. Loss of ERK5, following siRNA-
mediated downregulation, resulted in increased levels of cleaved
caspase-3 only in HDMECs plated in a collagen gel, an effect that
could not be reversed by addition of VEGF for 6 hours (Fig.
4G,H). Addition of STS was sufficient to induce the appearance of
the 17 kDa and 19 kDa cleaved caspase-3 fragments on both
gelatin and collagen matrices (Fig. 4G,H). Taken together, these
data show that under conditions of tubular morphogenesis, ERK5
is crucial for mediating VEGF-stimulated AKT activation, and the
resultant suppression of caspase-3 activity, facilitating endothelial
cell survival. Conversely, on a gelatin matrix, where proliferation
occurs, ERK5 is partly required for VEGF-mediated AKT
activation, but is not required for suppression of caspase-3 activity
or endothelial cell survival.
Constitutive activation of ERK5 in HDMECs leads to
activation of AKT and suppression of caspase-3 activity
To confirm the role of ERK5 in the regulation of AKT activation
and suppression of cleaved caspase-3 levels, we manipulated ERK5
activity by transiently transfecting HDMECs with plasmids
expressing either Flag-tagged wild-type ERK5 [ERK5(wt)], or
Flag-tagged dominant-negative ERK5 [DN-ERK5(AEF)], which
cannot be phosphorylated by MEK5, together with hemagglutinin
(HA)-tagged constitutively active MEK5 [CA-MEK5(D)]. In
agreement with previous studies (Barros and Marshall, 2005;
Schweppe et al., 2006), co-transfection of HDMECs with
ERK5(wt) and CA-MEK5(D) induced an increase in ERK5
phosphorylation (Fig. 5). This increase in ERK5 phosphorylation
was augmented by stimulation with VEGF, and blocked by co-
transfection of DN-ERK5(AEF) and CA-MEK5(D) (Fig. 5). Co-
transfection of ERK5(wt) and CA-MEK5(D) resulted in enhanced
phosphorylation of AKT on both Ser473 and Thr308 in both the
absence and the presence of VEGF (Fig. 5). Furthermore, enhanced
phosphorylation of BAD on Ser136 and increased expression of
BCL2 was also observed (Fig. 5). Analysis of cleaved caspase-3
levels revealed that expression of ERK5(wt) and CA-MEK5(D)
resulted in suppression of cleaved caspase-3 levels even in the
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Fig. 4. Downregulation of ERK5 induces activation
of caspase-3/7 during tubular morphogenesis.
HDMECs were transfected with 10 nM ERK5 siRNA1,
10 nM ERK5 siRNA2, 10 nM non-silencing (N.S.)
siRNA or left untransfected (Untrans.). 24 hours after
transfection, cells were serum starved for 20 hours,
before plating on a gelatin matrix, or between two layers
of a collagen I gel. Cells were stimulated with VEGF
(50 ng/ml) and/or 50 mM staurosporine (STS), as
indicated. Cells were lysed in Caspase-Glo® 3/7 reagent
at 1 hour (A,B), 6 hours (C,D) or 24 hours (E,F) after
treatment with VEGF or STS. Data are presented as
percentage of maximal caspase-3/7 activity (n3; mean
± s.d.). (G,H)6 hours after stimulation with VEGF, or
following treatment with 50 mM staurosporine (STS), as
indicated, cells were lysed in LDS buffer, and separated
on a 4–12% gradient NuPAGE® gel, followed by
western blot (WB) analysis with antibodies directed
against ERK5, cleaved caspase-3 and actin, as indicated.
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absence of VEGF (Fig. 5). Co-expression of DN-ERK5(AEF) and
CA-MEK5(D) did not stimulate ERK5 phosphorylation, AKT
phosphorylation, BAD phosphorylation or BCL2 expression under
basal conditions. Furthermore, DN-ERK5(AEF) and CA-MEK5(D)
co-expression blocked VEGF-stimulated ERK5 phosphorylation,
AKT phosphorylation and BAD phosphorylation. VEGF-mediated
increase in BCL2 expression and suppression of cleaved caspase-
3 was also blocked by co-expression of DN-ERK5(AEF) and CA-
MEK5(D) (Fig. 5). Taken together, these results confirm our
previous biochemical analysis with siRNA-mediated silencing of
ERK5, in that ERK5 regulates activation of AKT and the
downstream activation of BAD, resulting in suppression of caspase-
3 activity, which ultimately leads to HDMEC survival on a collagen
matrix.
Constitutive activation of ERK5 stimulates and sustains
VEGF-induced tubular morphogenesis
In accordance with the lack of effect of siRNA-mediated
downregulation of ERK5 upon HDMEC proliferation, co-
transfection of HDMECs with either ERK5(wt) and CA-MEK5(D),
or co-transfection of DN-ERK5(AEF) and CA-MEK5(D) had no
effect upon VEGF-stimulated cellular proliferation (Fig. 6). Co-
transfection of ERK5(wt) and CA-MEK5(D) stimulated HDMEC
tubular morphogenesis in the absence of VEGF over 24 hours (Fig.
7A,B) and sustained VEGF-stimulated tubular morphogenesis
for 5 days (Fig. 7C,D). Normal VEGF-stimulated tubular
morphogenesis in this assay is maximal after 24 hours, and tubes
rapidly regress after this time period; therefore the effect of
sustaining VEGF-induced tube formation for 5 days was significant.
By contrast, co-transfection of HDMECs with DN-ERK5(AEF)
and CA-MEK5(D), did not stimulate tubular morphogenesis under
basal conditions, and blocked VEGF-stimulated morphogenesis
over 24 hours and 5 days (Fig. 7A–C). Together, these data
demonstrate that ERK5 activity is essential for VEGF-stimulated
tube formation, but is dispensable for VEGF-stimulated
proliferation of HDMECs.
ERK5 activity is required for VEGF-stimulated
angiogenesis in a HDMEC and NHDF co-culture assay
The ability of ERK5 to regulate tubular morphogenesis in HDMECs
in a collagen gel suggested that ERK5 has the potential to regulate
VEGF-stimulated angiogenesis. We used an endothelial and
fibroblast co-culture assay to model events in a more representative
assay of in vivo angiogenesis (Donovan et al., 2001; Sorrell et al.,
2007). HDMECs were plated on a monolayer of normal human
dermal fibroblasts (NHDFs) and either left unstimulated or
stimulated with VEGF over a period of 5 days. The cells were then
stained for expression of the endothelial-specific marker CD31
and visualised by immunohistochemistry. Quantification of the
tubular networks showed that VEGF-stimulation of co-cultures
resulted in a threefold increase in the endothelial tubular network
after 5 days (Fig. 8A,B). siRNA-mediated silencing of either ERK5
or MEK5, using two individual duplexes directed against each
target, resulted in a profound inhibition of both basal, and VEGF-
stimulated tubule formation (Fig. 8A,B). The expression, and
efficient siRNA-mediated knockdown of ERK5, in both NHDFs
and HDMECs after 5 days was confirmed by western blotting (Fig.
8C). Analysis of cleaved caspase-3 levels in HDMEC and NHDF
co-cultures by immunofluorescence revealed that siRNA-mediated
silencing of ERK5 resulted in an increase in cleaved caspase-3,
which co-localised with the CD31-positive HDMECs within the
co-culture (Fig. 8D). Taken together, these results not only confirm
our previous observation in collagen gels that ERK5 is required for
VEGF-stimulated tubular morphogenesis, but also suggest that
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Fig. 5. Co-transfection of ERK5 and constitutively active MEK5(D)
stimulates phosphorylation of ERK5 and AKT and induces expression of
BCL2 whilst suppressing caspase-3 activity. HDMECs were transiently
transfected with 2.5g ERK5(wt) and 2.5g CA-MEK5(D), with 2.5g DN-
ERK5(AEF) + 2.5g CA-MEK5(D) or mock-transfected with 5.0g empty
pcDNA3.1 (Vector). 24 hours after transfection, HDMECs were serum-starved
for 20 hours before plating between two layers of collagen I and stimulation
with VEGF (50 ng/ml) for 24 hours. Cells were stimulated again with VEGF
(50 ng/ml) for 10 minutes before lysis in LDS sample buffer. Proteins were
separated by SDS-PAGE followed by western blot (WB) analysis. The degree
of phosphorylation of ERK5, AKT Ser473, AKT Thr308, BAD Ser136 and the
expression levels of ERK5 and BCL2 relative to actin was quantified by
densitometric analysis. Results are from one experiment, which is
representative of three.
Fig. 6. Co-transfection of ERK5 and constitutively active MEK5(D) does
not stimulate HDMEC proliferation. HDMECs were transiently transfected
with 2.5g ERK5(wt) and 2.5g CA-MEK5(D), 2.5g DN-ERK5(AEF) +
2.5g CA-MEK5(D) or mock-transfected with 5.0g empty pcDNA3.1
(Vector). 24 hours after transfection, HDMECs were seeded at 1.5104
cells/well on gelatin-coated 24-well plates. 24 hours after seeding, cells were
serum starved for 20 hours, before stimulation with VEGF (50 ng/ml). 72
hours after stimulation, cell numbers were quantified by CellTiter-Glo®
luminescence assay. Data are presented as cell number (n3; mean ± s.d.; n.s.,
not significant).
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endothelial cells have a specific requirement for ERK5 to suppress
caspase-3 activation and ultimately facilitate VEGF-mediated
survival and tubular morphogenesis in endothelial cells.
Discussion
Angiogenesis is a complex, multi-faceted process that requires the
coordinated migration, proliferation and ultimate differentiation of
endothelial cells to form a lumen-containing tubular vessel capable
of allowing blood flow. We have used a model system to analyse
the role of VEGF-mediated ERK5 activity in HDMECs during
proliferation and differentiation. Our results are the first to reveal
that ERK5 is specifically required for VEGF-mediated tubular
morphogenesis, but is dispensable for cellular proliferation in
primary HDMECs. We further define a specific role for ERK5 in
the regulation of VEGF-mediated AKT phosphorylation and the
suppression of caspase-3 activity during tubular morphogenesis,
revealing that ERK5 regulates a defined component of VEGF-
stimulated angiogenesis in endothelial cells.
VEGF stimulates a number of intracellular signalling pathways
that regulate cellular proliferation, migration and survival (Holmes
et al., 2007). VEGF has been reported to stimulate ERK5 activity in
human umbilical vein endothelial cells (HUVECs) and mouse lung
capillary endothelial cells (MLCECs) (Hayashi et al., 2004).
However, the potential role of ERK5 in the mediation of VEGF-
induced physiological responses had not been previously explored.
In contrast to ERK1/2, VEGF-mediated activation of ERK5 was
sustained under conditions of both proliferation and differentiation,
with a very similar kinetic profile of activation (Fig. 1C,D). Reduction
of ERK5 levels by siRNA-mediated gene silencing, revealed a
specific role for ERK5 in the regulation of VEGF-mediated HDMEC
tubular morphogenesis (Fig. 2C), but not proliferation (Fig. 2B).
siRNA-mediated silencing of MEK5 also prevented tubular
morphogenesis (supplementary material Fig. S2). The importance of
ERK5 in the specific regulation of tubular morphogenesis was
highlighted by the finding that co-expression of constitutively active
MEK5, together with ERK5, stimulated tubular morphogenesis in
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Fig. 7. Co-transfection of ERK5 and constitutively active MEK5(D) stimulates and sustains tubular morphogenesis in HDMEC. HDMECs were transiently
transfected with 2.5g ERK5(wt) + 2.5g CA-MEK5(D), 2.5g DN-ERK5(AEF) + 2.5g CA-MEK5(D) or mock-transfected with 5.0g empty pcDNA3.1
(Vector). 24 hours after transfection, HDMECs were serum starved for 20 hours, and seeded at 1.25105 cells per well between two layers of collagen I, before
stimulation with VEGF (50 ng/ml). 24 hours (A) and 5 days (C) after VEGF stimulation, cells were fixed, and the actin stress fibres and nuclei were stained with
Rhodamine-coupled Phalloidin (red) and Hoechst 33342 (blue), respectively. Results are from one experiment, which is representative of three. (B,D)The total
length of tubular structures was quantified from three fields (10 objective) per well (n3; mean ± s.d.; *P<0.05, **P<0.01). Scale bars: 100m.
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the absence of VEGF, and significantly sustained VEGF-stimulated
tubular morphogenesis (Fig. 7A–D). Activation of ERK5 has been
previously shown to regulate the differentiation of myoblasts (Dinev
et al., 2001), by regulating the pro-myogenic actions of IGF-2
(insulin-like growth factor 2) (Carter et al., 2009), suggesting that
ERK5 regulates the differentiation of a number of cell types.
The lack of any effect upon manipulation of ERK5 activity in
HDMECs, either by siRNA-mediated gene silencing (Fig. 2B) or
overexpression (Fig. 6), after VEGF-mediated proliferation,
suggests that in these cells, ERK5 activity is dispensable for this
response. By contrast, knockdown of ERK1/2 clearly affected
VEGF-mediated proliferation (supplementary material Fig. S1D),
in agreement with the established role of ERK1/2 in the regulation
of cell cycle entry (Brunet et al., 1999). The role of ERK5 in
regulating cell proliferation remains unclear. Although epidermal
growth factor (EGF)-mediated proliferation of fibroblasts (Kato et
al., 1998) and GM-CSF (granulocyte-macrophage colony-
stimulating factor)-mediated proliferation of haematopoietic cells
(Dong et al., 2001) are reported to be ERK5 dependent, other
research using cells from Erk5–/– and Mek5–/– mice has revealed
that ERK5 and MEK5 are not required for cell cycle progression
(Hayashi et al., 2004; Wang et al., 2005). The sensitivity of cells
on a collagen matrix to ERK5 downregulation is reflected in the
increased loss of VEGF-mediated activation of both AKT and
BAD on this matrix, following ERK5 silencing, compared with a
gelatin matrix (Fig. 3A). Activation of AKT requires its binding to
phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P3] via the
pleckstrin homology domain and phosphorylation at Thr308 in the
activation loop and phosphorylation at Ser473 in the C-terminus
(Alessi et al., 1996; Stokoe et al., 1997). The mammalian target of
rapamycin complex 2 (mTORC2) phosphorylates AKT at Ser473
(Jacinto et al., 2006; Sarbassov et al., 2005), whereas 3-
phosphoinositide-dependent kinase-1 (PDK1) phosphorylates AKT
at Thr308 (Alessi et al., 1996). VEGF-stimulated AKT activation
is regulated by phosphatidylinositol 3-kinase (PI3K) (Gerber et al.,
1998b; Thakker et al., 1999). However, VEGF-mediated ERK5
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Fig. 8. Downregulation of ERK5 expression prevents VEGF-stimulated angiogenesis in a HDMEC and NHDF co-culture assay. HDMECs were transfected
with 10 nM ERK5 siRNA1, 10 nM ERK5 siRNA2, 10 nM non-silencing (N.S.) siRNA or left untransfected (Untrans.). (A)24 hours after transfection, HDMECs
were plated onto a confluent NHDF monolayer, and treated with VEGF (50 ng/ml) or left unstimulated (Basal) with or without siRNA. (B)Total tubule area was
quantified by AngioQuant software. Data are presented as a percentage of maximum tube formation (n3; mean ± s.d.; **P<0.01). (C)48 hours after transfection
of NHDFs or HDMECs with ERK5 siRNA (5 nM ERK5 siRNA1 + 5 nM ERK5 siRNA2), or with non-silencing (N.S.) siRNA (10 nM), cells were lysed and
separated on a 10% SDS-PAGE gel followed by western blotting (WB) with antibodies directed against ERK5 and actin, as indicated. Expression of ERK5 relative
to actin was quantified by densitometric analysis. (D)HDMEC and NHDF co-cultures transfected with ERK5 siRNA (10 nM) or with N.S. siRNA (10 nM), and
stimulated with VEGF were fixed and stained with anti-CD31 (red) or with cleaved caspase-3 (Asp175) antibody Alexa Fluor® 488 conjugate (green). Scale bars:
400m. Results are from one experiment, which is representative of three.
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activation was not inhibited by either the PI3K inhibitor
wortmannin, or the mTOR inhibitor rapamycin (supplementary
material Fig. S3), suggesting that ERK5 is not downstream of
either PDK1 or mTORC2. Furthermore, the ability of both
wortmannin and chronic exposure to rapamycin (Sarbassov et al.,
2006) to inhibit VEGF-mediated phosphorylation of AKT and
BAD, without inhibiting ERK5 activity, confirmed that the classical
PI3K–PDK1 and mTORC2 pathways are able to regulate AKT
phosphorylation and that AKT phosphorylation is required for the
subsequent phosphorylation of BAD (supplementary material Fig.
S3). The precise mechanism of ERK5-mediated regulation of AKT
activity remains obscure. It is possible that ERK5 regulates the
activity of a phosphatase, such as PP2A, which has been shown to
interact with 1 integrin and dephosphorylate AKT at both Ser473
and Thr308 (Pankov et al., 2003). The recent finding that ERK5
immunoprecipitates with integrins 1, v3 and v5 in breast
cancer cells (Sawhney et al., 2009), raises the possibility that
ERK5 binds to specific integrins to coordinate signals from both
the cell matrix and VEGFR-2 to regulate AKT phosphorylation
and facilitate tubular morphogenesis in endothelial cells.
A role for Erk5 in the regulation of Akt phosphorylation at
Ser473 and Thr308 has previously been reported in mouse
embryonic fibroblasts under conditions of osmotic stress (Wang et
al., 2006). In mouse neuronal cells, nerve growth factor (NGF)-
mediated phosphorylation of Akt on Ser473, but not Thr308, is
dependent upon ERK5 activity (Finegan et al., 2009). Recently, it
has been shown that Erk5 regulates PDGF-stimulated Akt
phosphorylation at Ser473 in porcine aortic endothelial (PAE) cells
(Lennartsson et al., 2010). This suggests that ERK5 regulates AKT
activity in response to various agonists in different cells.
Activation of AKT is important for the regulation of apoptosis
because it has been shown to phosphorylate the pro-apoptotic
protein BAD on Ser136, leading to its cytosolic sequestration by
14-3-3 protein (Datta et al., 1997). Furthermore, AKT also regulates
expression of the anti-apoptotic protein BCL2 (Pugazhenthi et al.,
2000). BCL2 and BAD heterodimerise and neutralise each others’
function. BCL2 regulates apoptosis by preventing the release of
cytochrome c from the mitochondria and the sequential activation
of the initiator caspase-9 and terminal executioner caspase-3
pathway, ultimately resulting in endonuclease-mediated degradation
of DNA, cytoplasmic and chromatin condensation and cell death
(Cory et al., 2003). Consistent with the role of AKT in regulating
apoptosis, we found that knockdown of ERK5 prevented VEGF-
mediated phosphorylation of BAD (Fig. 3A) and also prevented
expression of BCL2 mRNA in HDMECs plated in a collagen gel
(Fig. 3B). ERK5 knockdown also induced caspase-3 activation on
this matrix (Fig. 4A–H). Conversely, constitutive activation of
ERK5 resulted in increased phosphorylation of BAD, increased
expression of BCL2 and suppressed activation of caspase-3 (Fig.
5). VEGF has previously been reported to increase BCL2 levels in
HUVECs (Gerber et al., 1998a) and to enhance HDMEC survival
in collagen gels (Nor et al., 1999), whereas increased BAD
phosphorylation has been shown to prevent apoptosis in rat
sinusoidal endothelial cells (Ohi et al., 2006). Our data show that
ERK5 is crucial for regulation of the apoptotic balance of these
signalling molecules.
Gene ablation of Erk5 in mice results in embryonic lethality at
around E10.5 as a result of abnormal cardiovascular development
(Regan et al., 2002; Sohn et al., 2002; Yan et al., 2003). Histological
analysis of the Erk5-null embryos has revealed that the vascular
endothelial cells are irregularly aligned, and undergo apoptosis,
resulting in defective angiogenesis. Previous data has also shown
that ERK5 is required to protect endothelial cells against fluid
shear stress (Pi et al., 2004). The requirement for ERK5 activity to
protect endothelial cells from apoptosis has been ascribed to the
need for ERK5-mediated phosphorylation of the myocyte enhancer
factor 2C (MEF2C) transcription factor (Hayashi et al., 2004).
This is based on the fact that the phenotype of Mef2c–/– mice is
similar to that of Erk5–/–mice, with embryonic lethality resulting
from cardiac and vascular malformations (Hayashi and Lee, 2004;
Roberts et al., 2009). However, infection of Erk5–/– embryos with
an adenovirus encoding a constitutively active Mef2c was only
able to partially protect endothelial cells from apoptosis (Hayashi
et al., 2004), suggesting the existence of additional effectors
downstream of ERK5 that regulate apoptosis (Olson, 2004).
Our data reveal that ERK5 is able to regulate VEGF signalling
in human endothelial cells, providing a mechanism for the adverse
effects on angiogenesis seen in murine Erk5–/– embryos. Conditional
knockouts of Erk5 in specific cell types including cardiomyocytes,
hepatocytes and neuronal cells develop normally (Hayashi and
Lee, 2004), suggesting that endothelial cells have a particular
requirement for ERK5. Current anti-angiogenic drug therapy is
centred around the development of inhibitors that target the VEGF
ligand or VEGFR-2 (Holmes et al., 2007), which inhibit all the
actions of VEGF on endothelial cells. Our results, showing that
ERK5 specifically regulates tubular morphogenesis rather than
proliferation, suggest that drugs targeting the ERK5 pathway in
vivo may uniquely allow selective interference of a specific
component of angiogenesis.
Materials and Methods
Cell culture
HDMECs and NHDFs were purchased from Promocell (Heidelberg, Germany). All
cells were routinely grown on gelatin-coated cell culture dishes [1% w/v gelatin
from porcine skin (Sigma, Poole, UK)]. HDMECs at passages (p) 2–8 were grown
in EBM MV2 growth medium (Promocell) containing 5% v/v foetal calf serum
(FCS), EGF (5 ng/ml), hydrocortisone (0.2 g/ml), VEGF (0.5 ng/ml), FGF-2 (10
ng/ml), insulin-like growth factor-1 (20 ng/ml) and ascorbic acid (1 g/ml). NHDFs
(p 4–12) were grown in fibroblast growth medium (Promocell) supplemented with
FGF-2 (1 ng/ml) and insulin (5 g/ml). All cells were incubated at 37°C in humidified
air containing 5% v/v CO2.
Cell stimulation and preparation of cell lysates
Before stimulation with VEGF, HDMECs were serum-starved for 20 hours in EBM
MV2 basal medium containing 1% (v/v) FCS. Cells were stimulated with 50 ng/ml
VEGF-A165 (Peprotech, Rocky Hill, NJ), washed in ice-cold Dulbecco’s phosphate-
buffered saline (DPBS) (Lonza, Basel, Switzerland) and lysed on ice in modified
RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2.5 mM EDTA, 10% (v/v)
glycerol, 1% (v/v) Triton X-100, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate,
1 mM sodium orthovanadate, 10 g/ml aprotinin, 10 g/ml leupeptin and 1 mM
phenylmethylsulfonylfluoride). Lysates were clarified by centrifugation (23,000 g
for 20 minutes at 4°C). For detection of cleaved caspase-3, cells were lysed in LDS
sample buffer (Invitrogen, Paisley, UK) containing 5% (v/v) -mercaptoethanol
(Sigma). Protein extracts were sonicated for 10 seconds using a Soniprep 150
sonicator (Sanyo-Gallenkamp, Leicester, UK) before heat denaturation at 90°C for
5 minutes.
Western blot analysis
Proteins were resolved by SDS-PAGE on NuPAGE® 10% or 4–12% pre-cast gradient
gels (Invitrogen) and transferred onto Hybond-C Extra nitrocellulose membranes
(GE Healthcare, Amersham, UK). Membranes were blocked using 5% (w/v) bovine
serum albumin (BSA) in Tris-buffered saline containing 0.01% (v/v) Tween 20
(TBST). Membranes were probed overnight with primary antibodies, diluted in
TBST containing 2% (w/v) BSA, or 5% (w/v) non-fat milk, directed against: ERK5;
AKT; Flag-Tag (DYKDDDDK Tag), HA-Tag (6E2), phospho-VEGFR-2 (Tyr1175);
phospho-ERK5 (Thr218/Tyr220); phospho-p44/42 MAP kinase (Thr202/Tyr204);
phospho-AKT (Thr308); phospho-AKT (Ser473); phospho-p70 S6 kinase
(Thr389)(108D2); phospho-BAD (Ser136); Bcl-2 (Human Specific); and cleaved
caspase-3 (Asp175) (New England Biolabs, Hitchin, UK). A primary antibody
directed against MEK5 (H-94) was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). An antibody directed against Actin (C-11) or Lamin B1 (H-90) (Santa
3197ERK5 regulates VEGF-mediated survival
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Cruz Biotechnology) was used to assess protein loading in all western blot
experiments. Proteins were detected using rabbit-specific secondary antibodies and
ECL (enhanced chemiluminescence) western blotting detection reagents (GE
Healthcare).
Quantitative real-time PCR (qRT-PCR) analysis
Total RNA was extracted using the RNeasy kit (Qiagen, Crawley, UK) according to
the manufacturer’s instructions. Harvested RNA was treated with DNaseI (Qiagen)
before first-strand cDNA synthesis carried out by reverse transcription of 1 g total
RNA using oligo(dT)18 and M-MLV Reverse Transcriptase (Invitrogen). Reaction
mixtures for qRT-PCR contained 1.5 l cDNA template, 4.5 l distilled H2O, 10 l
2 Power SYBR® Green mastermix (Applied Biosystems, Warrington, UK) and
0.25 M forward and reverse primers (Invitrogen) in each case. Primers used were:
ERK5, Hs_MAPK7_1_SG QuantiTect Primer Assay (Qiagen); BCL2 forward, 5-
GTC TGG GAA TCG ATC TGG AA-3, and BCL2 reverse, 5-GCA ACG ATC
CCA TCA ATC TT-3; -actin forward, 5-ATG GAT GAT GAT ATC GCC GC-3
and -actin reverse, 5-AAG CCG GCC TTG CAC AT-3. qRT-PCR reactions were
performed on a 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster
City, CA) with the following parameters: 50°C for 2 minutes and 95°C for 10
minutes followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Cycle
threshold (CT) values for the mRNA of interest and for the -actin control were
recorded, and changes in gene expression were determined by the Comparative CT
(2-CT) method (Livak and Schmittgen, 2001).
Transfection of siRNA
ERK5-specific short interfering RNA (siRNA) duplexes directed against the target
sequences 5-CAG ACC CAC CTT TCA GCC TTA-3 for Hs_MAPK7_9_HP
(designated ERK5 siRNA1) and 5-CAG GAT GGC CAG GCA GAT TCA-3 for
Hs_MAPK7_5_HP (designated ERK5 siRNA2), and MEK5-specific siRNA directed
against the target sequences 5-AAG ACG TAT GTT GGA ACA AAT-3 for
Hs_MAP2K5_11_HP (designated MEK5 siRNA1) and 5-CAA GAC GTA TGT
TGG AAC AAA-3 for Hs_MAP2K5_12_HP (designated MEK5 siRNA2), ERK1-
and ERK2-specific siRNA duplexes, directed against the target sequences 5-CTC
CCT GAC CCG TCT AAT ATA-3 for Hs_MAPK3_7 HP (designated ERK1 siRNA)
and 5-AAG TTC GAG TAG CTA TCA AGA-3 for HS_MAPK1_10 HP (designated
ERK2 siRNA) and a non-silencing (N.S.) control siRNA, directed against the
sequence 5-AAT TCT CCG AAC GTG TCA CGT-3, were purchased from Qiagen.
All siRNA duplexes were validated by qRT-PCR and western blotting prior to use
(Holmes et al., 2010). HDMECs were seeded at 1105 cells per well, on gelatin-
coated six-well dishes in 2 ml EBM MV2 growth medium, and incubated for 24
hours. Transfection was carried out in a total volume of 2.5 ml per well of OptiMEM
medium (Gibco, Paisley, UK) containing 10 nM siRNA and 0.1% (v/v)
LipofectamineTM RNAiMAX (Invitrogen). Cells were incubated with the transfection
mix for 4 hours before washing in DPBS containing Ca2+ and Mg2+ and the addition
of EBM MV2 growth medium. Cells were incubated for a further 24 hours before
lysis and immunoblotting. Alternatively, after washing, HDMECs were serum-
starved overnight in EBM MV2 basal medium containing 1% (v/v) FCS for use in
cell-based assays..
Plasmid constructs
Wild-type Flag-tagged ERK5 (pcDNA3.1BMK1); dominant-negative Flag-tagged
ERK5 [pcDNA3.1BMK1(AEF)] and constitutively active HA-tagged, MEK5
[pCMV5MEK5(D)] plasmids were kindly donated by Prof. Jiing-Dwan Lee (Scripps
Research Institute, La Jolla, CA) (Kato et al., 1997). Constitutively active HA-
tagged MEK5 was digested from pCMV5MEK5(D) with XbaI and KpnI (New
England Biolabs) and subcloned into pcDNA3.1 (Invitrogen).
Transfection of plasmid constructs
HDMECs were seeded on six-well gelatin-coated cell culture plates at 9.3104 and
incubated for 24 hours. Growth medium was replaced with 2 ml fresh EBM MV2
growth medium immediately before transfection. Plasmid DNA (2.5 g) was mixed
with serum-free OptiMEM medium and transfected using TransPassTM HUVEC
Transfection Reagent (New England Biolabs) according to the manufacturer’s
instructions. Cells were incubated with transfection mix for 4 hours, washed twice
in DPBS followed by the addition of EBM MV2 growth medium. Cells were
incubated for 24 hours, and serum starved in EBM MV2 medium containing 1%
(v/v) FCS before use in assays.
3D collagen gel tube formation assay
PureColTM type I collagen was purchased from Inamed Biomaterials (Leimuiden,
The Netherlands). Collagen gels were prepared as described previously (Bohman et
al., 2005). Serum-starved HDMECs were seeded at 1.25105 cells per well of a 24-
well plate before the addition of the top layer of collagen, and stimulation with
VEGF (50 ng/ml) for 20 hours. Length of tubular structures was quantified using
NIH ImageJ software as described previously (Matsumoto et al., 2002).
HDMEC and NHDF co-culture angiogenesis assay
NHDFs were seeded in fibroblast growth medium at 1.5104 cells per well on
gelatin-coated 24-well plates and incubated for 3 days. On day 4, HDMECs treated
with siRNA, or not, were seeded at 4.5103 cells per well, on top of the NHDF
monolayer in EBM MV2 growth medium. On day 5, co-cultures were transfected
with siRNA (as described above) for 4 hours, followed by washing in DPBS, and
replacement of EBM MV2 growth medium. On day 6, cells were placed in EBM
MV2 basal medium containing 1% (v/v) FCS with, or without, 50 ng/ml VEGF.
On days 7 and 9, co-cultures were treated with siRNA, as described above. On day
8, cells were placed in fresh EBM MV2 medium containing 1% (v/v) FCS with,
or without, 50 ng/ml VEGF. On day 10, co-cultures were fixed in ice-cold 70%
(v/v) ethanol for 30 minutes before addition of blocking buffer (1% (w/v) BSA in
DPBS) for 30 minutes. Monoclonal mouse anti-human CD31 antibody, (Dako
Cytomation, Glostrup, Denmark) (1:750 dilution in blocking buffer) was added for
1 hour at 37°C, followed by three washes in blocking buffer. Anti-mouse IgG
(whole molecule) alkaline-phosphatase-conjugated antibody (Sigma) was diluted
1:200 in blocking buffer and incubated for 1 hour at 37°C. Tubes formed from
endothelial cells were visualised by the addition of the substrate SigmaFastTM
BCIP/NBT (5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium) solution
(Sigma).
Quantification of tube formation in HDMEC and NHDF co-cultures
Tube formation in co-culture plates was analysed by photographing three randomly
selected fields of view, in triplicate wells per condition, at low magnification (4
objective) using a Nikon Eclipse TS 100 microscope attached to a Nikon DS-Fi1-
L2 digital camera (Nikon, Kingston upon Thames, UK). Total tubule length was
quantified using AngioQuant software (http://www.cs.tut.fi/sgn/csb/angioquant/)
(Niemisto et al., 2005).
Immunostaining
HDMECs undergoing tubular morphogenesis in 3D collagen gels were fixed with
paraformaldehyde and stained with Phalloidin as described previously (Mellberg et
al., 2009). When detecting cleaved caspase-3 within co-cultures, fixed co-cultures
were blocked in blocking buffer [5% (v/v) normal goat serum (Vector Laboratories,
Burlingame, CA) in DPBS containing 0.3% (v/v) Triton X-100] at 37°C for 30
minutes. Monoclonal mouse anti-human CD31 antibody (Dako Cytomation) was
diluted 1:750, together with a 1:10 dilution of cleaved caspase-3 (Asp175) antibody
Alexa Fluor® 488 conjugate (New England Biolabs) in 1% (w/v) BSA in DPBS
containing 0.2% (v/v) Triton X-100. Cells were incubated with the antibody solution
overnight, in the dark, at 4°C with gentle rocking. Cells were washed, and incubated
with Alexa Fluor® 568 goat anti-mouse IgG (Molecular Probes) diluted 1:200 in 1%
(w/v) BSA in DPBS, in the dark, at room temperature for 2 hours. Finally, cells were
washed in ddH2O, and analysed using a Nikon TE2000 inverted fluorescence
microscope. 
Cell proliferation assay
HDMECs were seeded at 1.5104 cells per well in 24-well plates in EBM MV2
growth medium. After 24 hours, cells were washed in DPBS and serum-starved in
1 ml EBM MV2 medium containing 1% (v/v) FCS for 20 hours. Cells were
stimulated, or not, with VEGF (50 ng/ml) and incubated for a further 72 hours. Cell
numbers were quantified using a Cell Titer-GloTM luminescent cell viability assay
reagent (Promega, Southampton, UK), as previously described (Crouch et al., 1993).
Luminescence was measured on a Wallac Victor2 1420 Multilabel Counter (Perkin
Elmer Life Sciences, Fremont, CA).
Cell cycle analysis
Determination of the cell cycle distribution was carried out by FACS analysis as
described previously (Mellberg et al., 2009).
Annexin V apoptosis assay
Early apoptosis of HDMECs was detected as described previously (Dimberg et al.,
2008).
Fluorogenic caspase-3/7 assay
HDMECs on gelatin or collagen matrices in 24-well plates were washed briefly in
DPBS before complete cell lysis in Caspase-Glo® 3/7 reagent (Promega). Aliquots
of the resultant lysates were transferred into separate wells of black-walled 96-well
plates, and luminescence was measured using a Wallac Victor2 1420 Multilabel
Counter.
Signal transduction inhibitors
Rapamycin and wortmannin were purchased from Calbiochem (Merck Chemicals
Ltd, Nottingham, UK) and reconstituted in DMSO (Sigma). Cells were pre-incubated
with indicated amounts of signal transduction inhibitors for the times shown in EBM
MV2 basal medium containing 1% (v/v) FCS at 37°C, before stimulation with
VEGF.
Statistical analysis
Results are expressed as mean ± s.d. Statistical analyses using an unpaired Student’s
t-test were performed using SPSS (version 16.0), with P<0.05 considered to be
significant.
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